Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Inv. presentation
Director comp.
|
|
Assertio Therapeutics, Inc (ASRT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T... |
| 05/11/2020 |
8-K
| Quarterly results |
| 04/24/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 04/08/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/17/2020 |
8-K
| Asset disposition|
Docs:
|
"Agreement and Plan of Merger by and among Assertio Therapeutics, Inc., Alligator Zebra Holdings, Inc., Alligator Merger Sub, Inc., Zebra Merger Sub, Inc. and Zyla Life Sciences",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Transition Agreement by and among Assertio Therapeutics, Inc. and Arthur Higgins",
"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company",
"Employee FAQs",
"Investor Presentation" |
|
| 03/11/2020 |
8-K
| Quarterly results |
| 03/09/2020 |
8-K
| Quarterly results |
| 02/20/2020 |
8-K
| Quarterly results |
| 02/13/2020 |
8-K
| Quarterly results |
| 02/07/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 01/16/2020 |
8-K/A
| Financial Statements and Exhibits |
| 01/13/2020 |
8-K
| Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Regulation FD Disclosure, ... |
| 12/12/2019 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Asset Purchase Agreement, by and among Assertio Therapeutics Inc., Golf Acquiror LLC and, solely for the purposes set forth therein, Celtic Intermediate S.A",
"Sixth Amendment to Note Purchase Agreement, by and among Assertio Therapeutics, Inc., certain subsidiaries of Assertio Therapeutics, Inc. party thereto, certain noteholders party thereto and Deerfield Private Design Fund III, L.P., as collateral agent",
"Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million" |
|
| 11/06/2019 |
8-K
| Quarterly results |
| 10/21/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 09/30/2019 |
8-K
| Quarterly results |
| 08/14/2019 |
8-K
| Regulation FD Disclosure |
| 08/09/2019 |
8-K
| Quarterly results |
| 08/09/2019 |
8-K
| Quarterly results |
| 08/07/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"ASSERTIO THERAPEUTICS, INC. AMENDED AND RESTATED 2014 OMNIBUS INCENTIVE PLAN 1. Plan. Assertio Therapeutics, Inc., a Delaware corporation , originally established the 2014 Omnibus Incentive Plan , effective as of February 19, 2014 . The Original Plan was most recently amended and restated in its entirety effective August 15, 2018 in connection with the Company’s name change and reincorporation. The Original Plan, as amended and restated through August 15, 2018, is hereby further amended and restated in its entirety . This Plan shall continue in effect for a term of 10 years after the Effective Date unless sooner terminated by action of the Board of Directors of the Company. 2. Objectives. This Plan is designed to attract and retain employees and consultants of the Company and its Subsidiar..." |
|
| 04/01/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/28/2019 |
8-K
| Other Events |
| 03/06/2019 |
8-K
| Quarterly results |
| 02/19/2019 |
8-K
| Quarterly results |
| 01/09/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 01/07/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"January 2019 About this Presentation The statements that are not historical facts contained in this presentation are forward-looking statements including, but not limited to, statements relating to the commercialization of Gralise, CAMBIA, and Zipsor, royalties associated with Collegium's commercialization of NUCYNTA and NUCYNTA ER, regulatory approval and clinical development of cosyntropin depot, our loan agreements, including our senior secured debt facility, and expectations regarding financial results and potential business and investment opportunities. These forward-looking statements involve significant risks and uncertainties, including risks detailed in the Company's Securities and Exchange Commission filings, including the Company's most recent Annual Report on Form 10-K and most..." |
|
| 11/08/2018 |
8-K
| Quarterly results |
| 11/08/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
Docs:
|
"Amendment No. 3 to Commercialization Agreement, by and among Assertio Therapeutics, Inc., Collegium Pharmaceutical, Inc., and Collegium NF, LLC",
"Consent, by and among Assertio Therapeutics, Inc., certain purchasers and Deerfield Private Design Fund III, L.P" |
|
| 10/29/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/13/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/28/2018 |
8-K
| Entry into a Material Definitive Agreement |
| 08/17/2018 |
8-K/A
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
|
|
|